# US 2020/0206349 A1 · Immunothermosensitive Composite, Kit For Treating Cancer, And Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206349 A1
- Document ID: US20200206349A1
- Status: Published application
- Kind: A1
- Application number: 16/407,912
- Filed: 2019-05-09
- Published: 2020-07-02
- Earliest claimed: 2018-12-26
- Assignees: National Tsing Hua University
- Applicants: National Tsing Hua University
- Inventors: Hsing-Wen Sung; Po-Ming Chen; Wen-Yu Pan; Cheng-Yu Wu; Ching-Yen Yeh; Po-Kai Luo; Chun-Ju Chou; Yung-Seng Pang; Yu-Miao Liu
- Web page: https://patentgrep.com/patent/US20200206349A1

## CPC

- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61K 9/5089: {Processes}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 41/0052: {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61N 5/0625: {Warming the body, e.g. hyperthermia treatment}
- A61P 35/00: Antineoplastic agents
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- A61N 5/067: using laser light
- A61N 2005/0659: {infrared}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An immunothermosensitive composition is provided in the present disclosure. The immunothermosensitive composition includes a carrier and an immune adjuvant. The shell is carrier formed by self-assembly of a hydrophilic amine-containing polymer and a conductive polymer to form a hydrophilic region and a hydrophobic region, and the hydrophilic region is located outside the hydrophobic region. The immune adjuvant is coated in the hydrophobic region of the carrier, wherein the immune adjuvant specifically binds to Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8). The immunothermosensitive composition can absorb light energy to generate thermal energy and is maintained at a temperature greater than or equal to 39° C. and less than or equal to 45° C.

## Claims

### Claim 1

An immunothermosensitive composition, comprising:
a carrier formed by self-assembly of a hydrophilic amine-containing polymer and a conductive polymer to form a hydrophilic region and a hydrophobic region, wherein the hydrophilic region is located outside the hydrophobic region, and the conductive polymer has a covalent π bond; and
an immune adjuvant coated in the hydrophobic region of the carrier, wherein the immune adjuvant specifically binds to Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8);
wherein the immunothermosensitive composition absorbs light energy to generate thermal energy and maintains a temperature greater than or equal to 39° C. and less than or equal to 45° C.

### Claim 2 (depends on 1)

The immunothermosensitive composition of claim 1, wherein the hydrophilic amine-containing polymer is glycol chitosan (GCS), gelatin, O-carboxymethyl chitosan (CMCS), albumin, poly-L-lysine (PLL) or polyetherimide (PEI).

### Claim 3 (depends on 1)

The immunothermosensitive composition of claim 1, wherein the conductive polymer is polyaniline (PANI), trans-polyacetylene (trans-PA), poly-p-phenylene (PPP), poly(p-phenylene vinylene) (PPV), poly(p-phenylene sulfide) (PPS), polypyrrole (PPy), polythiophene (PTh), poly(3,4-ethylenedioxythiophene) (PEDOT) or poly(9,9-di-n-octyl-2,7-fluorene) (PFO).

### Claim 4 (depends on 1)

The immunothermosensitive composition of claim 1, wherein the immune adjuvant is resiquimod, imiquimod, gardiquimod, CL097, 3M-003, CL075, TL8-506 or motolimod.

### Claim 5 (depends on 1)

The immunothermosensitive composition of claim 1, wherein per milligram of the carrier comprises 10 μg to 50 μg of the conductive polymer.

### Claim 6 (depends on 1)

The immunothermosensitive composition of claim 1, wherein a surface charge of the immunothermosensitive composition ranges from 10 mV to 50 mV.

### Claim 7 (depends on 1)

The immunothermosensitive composition of claim 1, wherein based on the immunothermographic composition is 100 parts by weight, a weight ratio of the carrier to the immune adjuvant is 80 parts by weight: 20 parts by weight to 95 parts by weight: 5 parts by weight.

### Claim 8 (depends on 1)

A kit for treating cancer, comprising:
the immunothermosensitive composition of claim 1; and
a light supply device for irradiating the immunothermosensitive composition.

### Claim 9 (depends on 8)

The kit for treating cancer of claim 8, wherein a light source of the light supply device is ultraviolet light (UV), near infrared light (NIR), far infrared light (FIR) or visible light (VIS).

### Claim 10 (depends on 1)

A method for treating cancer comprising administering an effective amount of the immunothermosensitive composition of claim 1 to a subject in need for a treatment of cancer.

### Claim 11 (depends on 10)

The method for treating cancer of claim 10, wherein the immunothermosensitive composition inhibits a cancer cell proliferation.

### Claim 12 (depends on 10)

The method for treating cancer of claim 10, wherein the immunothermosensitive composition inhibits a cancer metastasis.

### Claim 13 (depends on 10)

The method for treating cancer of claim 10, wherein the immunothermosensitive composition inhibits a cancer recurrence.

### Claim 14 (depends on 10)

The method for treating cancer of claim 10, wherein the immunothermosensitive composition triggers a tumor immune response.

### Claim 15 (depends on 10)

The method for treating cancer of claim 10, wherein the immunothermosensitive composition is used as a tumor vaccine.
